Please select the option that best describes you:
What pathologic response criteria do you use to determine the need for further adjuvant therapy in patients with breast cancer?
While the KATHERINE trial for HER2+ used path staging, CREATE-X for TNBC with capecitabine used the Japanese Breast Cancer Society response criteria. Is there any utility in using the residual cancer burden (RCB) for HR+ cases?
Answer from: Medical Oncologist at Academic Institution
The question about which response criteria might guide further adjuvant therapy in HR+ disease after neo-adjuvant chemo is of unclear clinical significance currently. Until CDK4/6 inhibitors receive an FDA indication in the adjuvant setting, the only "systemic therapy" decision to be made after neo-...
Sign in or Register to read more